Trial Profile

A Phase IIIB Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ocrelizumab (Primary) ; Diphenhydramine; Diphenhydramine; Methylprednisolone
Indications Multiple sclerosis
Focus Registrational; Therapeutic Use
Acronyms GAVOTTE
Sponsors Roche

31 May 2025 Planned primary completion date changed from 7 Apr 2025 to 28 Jul 2025.
11 Mar 2024 Planned End Date changed from 26 Jul 2029 to 8 Mar 2029.
11 Mar 2024 Planned primary completion date changed from 12 Nov 2025 to 7 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com